Josef Vormoor
Overview
Explore the profile of Josef Vormoor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
George S, Lynn C, Stankunaite R, Hughes D, Sauer C, Chalker J, et al.
Cancer Discov
. 2024 Dec;
PMID: 39693475
We profiled a large heterogenous cohort of matched diagnostic-relapse tumour tissue and paired plasma-derived cell free DNA (cfDNA) from patients with relapsed and progressive solid tumours of childhood. Tissue and...
2.
Bozovic Spasojevic I, Ferrari A, De Munter J, Gamble A, Konsoulova-Kirova A, Rizvi K, et al.
Tumori
. 2023 Jul;
109(6):546-554.
PMID: 37486101
Background: It is well documented that traditional health care models do not meet the specific needs of Adolescents and Young Adults (AYA) cancer patients. Methods: We explore a map of...
3.
Verwaaijen E, van der Torre P, Vormoor J, Pieters R, Fiocco M, Hartman A, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612316
Sarcopenia in pediatric hemato-oncology patients is undesirable because of the consequences it may have for treatment continuation and outcome, physical abilities and participation in daily life. An easy-to-use screening tool...
4.
Pal D, Blair H, Parker J, Hockney S, Beckett M, Singh M, et al.
Cell Rep Med
. 2022 Aug;
3(8):100717.
PMID: 35977468
Leukemia cells re-program their microenvironment to augment blast proliferation and enhance treatment resistance. Means of clinically targeting such niche-driven treatment resistance remain ambiguous. We develop human induced pluripotent stem cell...
5.
Tirtakusuma R, Szoltysek K, Milne P, Grinev V, Ptasinska A, Chin P, et al.
Blood
. 2022 Jul;
140(17):1875-1890.
PMID: 35839448
The fusion gene MLL/AF4 defines a high-risk subtype of pro-B acute lymphoblastic leukemia. Relapse can be associated with a lineage switch from acute lymphoblastic to acute myeloid leukemia, resulting in...
6.
Bomken S, Enshaei A, Schwalbe E, Mikulasova A, Dai Y, Zaka M, et al.
Haematologica
. 2022 Apr;
108(3):717-731.
PMID: 35484682
Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukemia (BCP-ALL) carries an immunoglobulin- MYC rearrangement (IG-MYC-r). This can result in diagnostic confusion with Burkitt lymphoma/leukemia and use of individualized treatment schedules...
7.
Menne T, Slade D, Savage J, Johnson S, Irving J, Kearns P, et al.
BMJ Open
. 2022 Mar;
12(3):e059872.
PMID: 35246426
Introduction: Event-free survival rates at 15 years for paediatric patients with relapsed/refractory acute lymphoblastic leukaemia (ALL) are 30%-50%, with 5-year survival for adult patients only 20%. Many patients with newly...
8.
Brivio E, Baruchel A, Beishuizen A, Bourquin J, Brown P, Cooper T, et al.
Eur J Cancer
. 2022 Feb;
164:1-17.
PMID: 35121370
Despite improved outcomes achieved in the last decades for children with newly diagnosed leukaemia and lymphoma, treatment of patients with refractory/relapsed disease remains a challenge. The cure rate is still...
9.
Van der Zwet J, Buijs-Gladdines J, Cordo V, Debets D, Smits W, Chen Z, et al.
Leukemia
. 2021 May;
35(12):3394-3405.
PMID: 34007050
(Patho-)physiological activation of the IL7-receptor (IL7R) signaling contributes to steroid resistance in pediatric T-cell acute lymphoblastic leukemia (T-ALL). Here, we show that activating IL7R pathway mutations and physiological IL7R signaling...
10.
Wolfs T, Attarbaschi A, Balduzzi A, Bernardo M, Bomken S, Borkhardt A, et al.
Hemasphere
. 2020 Sep;
4(5):e465.
PMID: 32984769
No abstract available.